Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Bibliographic Details
Main Authors:	Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court, J Paul O’Hare, David McGrane, Tim Holt, Norman Waugh
Format:	Article
Language:	English
Published:	NIHR Journals Library 2018-02-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta21020-c201802

Similar Items

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation
by: Rhona Johnston, et al.
Published: (2017-01-01)

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
by: Johnston, R, et al.
Published: (2017)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
by: Odette S Reifsnider, et al.
Published: (2021-03-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Sex-dependent effects of canagliflozin and dapagliflozin on hemostasis in normoglycemic and hyperglycemic mice
by: Natalia Marcińczyk, et al.
Published: (2023-01-01)

Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2023-04-01)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023-08-01)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
by: Erik Håkansson, et al.
Published: (2021-01-01)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
by: Xingyun Hou, et al.
Published: (2019-05-01)

Comparative Analysis of the Influence of Empagliflozin and Dapagliflozin on the Course of Heart Failure with Associated Pathology
by: Nadiia M. Kulaiets
Published: (2024-12-01)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
by: Hao Z, et al.
Published: (2022-07-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2024-02-01)

Renal and Glucose-Lowering Effects of Empagliflozin and Dapagliflozin in Different Chronic Kidney Disease Stages
by: Yi-Hsuan Lin, et al.
Published: (2019-11-01)

Real‐world data on Empagliflozin and Dapagliflozin use in patients with HEART failure: The RED–HEART study
by: Umut Kocabas, et al.
Published: (2025-02-01)

Corrigendum: Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2025-02-01)

Pharmacokinetic and pharmacodynamic drug–drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers
by: Dasohm Kim, et al.
Published: (2023-08-01)

Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
by: Hong-xia Ma, et al.
Published: (2024-12-01)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01)

Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy
by: Aneta Cinakova, et al.
Published: (2025-01-01)

Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review
by: Magdalena Kłusek, et al.
Published: (2024-07-01)

A novel HPLC method for the simultaneous determination of empagliflozin and dapagliflozin: Development, validation, robustness testing and greenness assessment
by: Kladi Eleftheria, et al.
Published: (2024-01-01)

Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022-11-01)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
by: Shuyan Gu, et al.
Published: (2016-01-01)

The genesis of Clough's poetry
by: McGrane, P, et al.
Published: (2008)

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation
by: N Waugh, et al.
Published: (2010-07-01)

Comparative Assessment of the Long-Term Effectiveness and Safety of Dapagliflozin and Empagliflozin as Add-on Therapy to Hypoglycemic Drugs in Patients with Type 2 Diabetes
by: Ai-Yu Yang, et al.
Published: (2022-01-01)

Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial
by: Luis Ricardo Balleza Alejandri, et al.
Published: (2024-06-01)

Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
by: Jayoung Lim, et al.
Published: (2022-01-01)

Losartan and dapagliflozin combination therapy in reducing uric acid level compared to monotherapy in patients with heart failure
by: Tuong Le Trong Huynh, et al.
Published: (2024-11-01)

Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
by: Yoshiro Fushimi, et al.
Published: (2020-01-01)

Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study
by: Jaehyun Lim, et al.
Published: (2023-07-01)

Self-monitoring of blood glucose in type 2 diabetes: systematic review
by: C Clar, et al.
Published: (2010-03-01)

Canagliflozin-Induced Diabetic Ketoacidosis
by: Jessica Turner MSIV, et al.
Published: (2016-08-01)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
by: Dimitrios Patoulias, et al.
Published: (2022-08-01)

The curious case of Queensland and a middle way for senior schooling assessment
by: McGrane, J
Published: (2018)

The bipolarity of attitudes: unfolding the implications of ambivalence
by: McGrane, J
Published: (2018)

Stevens’ forgotten crossroads: the divergent measurement traditions in the physical and psychological sciences from the mid-twentieth century
by: McGrane, J
Published: (2015)

Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
by: N Waugh, et al.
Published: (2010-09-01)

Comparison of the efficacy of dapagliflozin and linagliptin in the treatment of type 2 diabetes patients with normal body mass index and poor metformin monotherapy
by: Mingli He, et al.
Published: (2024-01-01)